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Objective:  The  aim  of  this  study  was  to  screen  for  diabetes  mellitus  in  leprosy
patients  to  elucidate  whether  leprosy  infection  may  play  a  role  in  the  pathogenesis
of  diabetes  mellitus  in  this  population.
Subjects  and  methods:  Thirty  patients  of  different  ages  and  of  both  sexes  with  var-
ious  types  of  leprosy  were  included  in  this  study.  In  addition,  15  healthy  individuals
of  comparable  age  and  sex  who  had  no  family  history  of  diabetes  mellitus  were  iden-
tiﬁed  as  controls.  In  both  groups,  determinations  of  fasting  and  postprandial  blood
sugar,  an  oral  glucose  tolerance  test  (OGTT),  measures  of  fasting  serum  insulin  and
pro-inﬂammatory  cytokine  tumor  necrosis  factor  alpha  (TNF), as  well  as  calcula-
tions  using  the  Homeostasis  Model  Assessment  for  Insulin  Resistance  (HOMA-IR),  were
carried  out.
Result:  Approximately  13.3%  of  the  leprosy  patients  were  diabetic,  and  37.7%  were
in  pre-diabetic.  The  highest  incidences  of  diabetes  and  pre-diabetes  were  in  lep-
romatous  leprosy  (10%  and  20%,  respectively);  a  lower  incidence  of  pre-diabetes
(6.6%)  was  observed  in  tuberculoid  leprosy;  and  the  lowest  incidence  of  diabetes
(0.0%)  was  noted  in  borderline  leprosy  patients.  Although  normal  healthy  persons
were  not  diabetic  (0%),  20%  were  pre-diabetic.
Conclusion:  This  study  revealed  that  the  incidence  of  diabetes  was  higher  in  the
leprosy  patients  than  in  the  control  group.  As  a  result,  we  recommend  that  all  leprosy
patients  should  be  screened  for  diabetes.
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ntroduction
eprosy  is  a  contagious  and  chronic  systemic  granu-
omatous  disease  caused  by  Mycobacterium  leprae,
n obligatory  intercellular  organism.  Although  it
s an  ancient  disease,  leprosy  remains  endemic
nd a  major  public  health  problem  in  Third  World
ountries.  In  non-endemic  areas,  because  of  the
ncreasing  rate  of  immigration  from  endemic  coun-
ries as  well  as  its  long  incubation  period,  knowl-
dge about  this  disease  is  important  for  differential
nd conclusive  diagnosis  [1].  Typically,  leprosy  has
 preference  for  peripheral  tissue,  as  the  leprae
acilli appear  to  survive  better  at  a  temperature
loser to  30 ◦C  than  37 ◦C.  Hence,  it  affects  the  skin,
eripheral  nerves,  the  mucosa  of  the  upper  airways
nd other  tissues,  such  as  bone  and  some  vis-
era [2].  However,  leprosy  is  a  pleiotropic  disease
hat can  resemble  many  dermatological  and  neu-
ological  diseases  and  can  affect  multiple  organs,
hus making  its  recognition  difﬁcult.  In  particu-
ar, the  endocrine  manifestations  of  leprosy  have
een underestimated,  even  by  specialists  [1].  A
haracteristic  feature  of  leprosy  is  its  unique  spec-
rum of  clinical  and  pathological  manifestations.
t one  pole  of  the  spectrum  is tuberculoid  (pau-
ibacillary)  leprosy,  and  at  the  opposite  pole  of
he spectrum  is  lepromatous  (multibacillary)  lep-
osy. There  is  a  borderline  group  between  these  two
oles that  can  be  divided  into  three  subgroups:  bor-
erline tuberculoid  (BT),  mid-borderline  (BB)  and
orderline  lepromatous  (BL)  [3].
There  is  a  universal  interest  in  diabetes  mel-
itus as  a  result  of  increasing  recognition  of  its
revalence  and  widespread  complications.  Every
hysician  has  to  suspect  diabetes  mellitus  in  a case
n which  there  is  difﬁculty  in  overcoming  an  episode
f infection.  Patients  with  diabetes  mellitus  have
n increased  susceptibility  to  bacterial  and  fun-




Table  1  Diabetic  status  of  patients  with  leprosy  and  norm
Diabetic  state  Leprosy  patients
n  =  30
No  of  cases  Inci
Non  diabetic  state  15  50  
Pre  diabetic  state  (latent  diabetes)  11  37.
Diabetic  state  (manifested  diabetes)  4  13.
* P < 0.05 (S = signiﬁcant).
** P < 0.01 (HS = highly signiﬁcant).
P > 0.05 (NS = non signiﬁcant).361
reater  problem  to  the  diabetic  than  to  the  non-
iabetic  patient.  Various  biochemical  changes  in
eprosy that  may  play  a  role  in  the  pathogenesis  of
iabetes mellitus  have  drawn  the  attention  of  many
linicians  in  recent  years.
The present  study  is  an  attempt  to  screen  for
iabetes mellitus  in  leprosy  patients  and  to  clar-
fy whether  a leprosy  infection  can  play  a  role  in
he pathogenesis  of  diabetes  mellitus  in  leprosy
atients.
ubjects and methods
hirty  patients  of different  ages  and  of  both  sexes
ith various  types  of  leprosy  were  included  in  this
tudy. The  study  was  conducted  at  the  Infectious
isease Hospital  (IDH),  Kuwait,  from  October  2009
o March  2011.  Of  the  patients  included  in  the  study,
5 were  Indian,  6  were  Indonesian,  5  were  Nepali,
 were  Bangladeshi  and  2  were  Sri  Lankan.  In  addi-
ion, 15  healthy  individuals  of  comparable  age,  race
nd gender  without  family  histories  of  diabetes
ellitus were  identiﬁed  as  controls.  All  the  leprosy
atients  were  diagnosed  by  clinical  examination
nd conﬁrmed  by  histopathological  examination  of
he lesions.  The  controls  and  the  leprosy  cases  were
ubmitted  to  a full  assessment  of  the  family  his-
ory, a thorough  clinical  examination,  a  calculation
f the  body  mass  index  (kg/m2),  a  liver  function
est (LFT),  a kidney  function  test  (KFT),  a complete
lood  count  (CBC),  a  fasting  blood  sugar  determina-
ion,  a  postprandial  blood  sugar  determination,  an
ral glucose  tolerance  test  (OGTT),  estimation  of
asting serum  insulin  levels  and  estimation  of  pro-
nﬂammatory  cytokine  tumor  necrosis  factor  alphaal Group,  SynLab,  Germany).  For  each  subject,
he Homeostasis  Model  Assessment  for  Insulin  Resis-
ance (HOMA-IR)  was  calculated  using  the  following
al  healthy  individuals.
Control
n =  15
dence  (%)  No  of  cases  Incidence  (%)  P  value
12  80  0.02*
S
7  3  20  1.0
NS
3  0  0  0.03**
HS
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Table  2  Diabetic  status  in  relation  to  clinical  types  of  leprosy  and  gender.
Clinical  type
of  leprosy
Number  of  cases  Incidence  of  diabetes
Male  Female  Total  Diabetic  state  Pre-diabetic  state
Male  Female  P  value  Male  Female  P  value
TT 4 (33.3)  5 (66.7)  9  1  (25.0)  0  (0.0)  0.44  1  (25.0)  1  (20.0)  1.0
Border 7 (63.6)  2 (36.4)  9 0 (0.0)  0 (0.0)  Can  not
computed
2  (28.5)  1  (50.0)  1.0
LL  5  (57.1)  7  (42.9)  12  2  (40.0)  1  (14.2)  0.52  3  (60.0)  3  (42.8)  1.0
Total  16  14  30  3  1  6  5
 leprosy.
Table  3  Mean  ±  SD  of  the  age  and  BMI  of  the  group
studied.
Age  BMI
Mean  ±  SD  Mean  ±  SD
Leprosy  patients  34.9  ±  6.5  21.7  ±  2.1


























nTT, tubercliod leprosy; BB, borderline leprosy; Ll, lepromatous
equation:  fasting  plasma  insulin  (U/ml)  ×  fasting
plasma glucose  (mmol/l)/22.5.  Matthews  et  al.
have suggested  that  insulin  resistance  is  highly  cor-
related with  this  index  [4].
The fasting  plasma  glucose  (measured  before
the OGTT  begins)  should  be  below  6.1  mmol/l
(110 mg/dl).  Fasting  levels  between  6.1  and
7.0 mmol/l  (110  and  125  mg/dl)  are  borderline
‘‘impaired fasting  glycemia’’.  Fasting  levels
repeatedly  at  or  above  7.0  mmol/l  (126  mg/dl)  are
diagnostic  of  diabetes.  The  2-h  OGTT  glucose  level
should be  below  7.8  mmol/l  (140  mg/dl).  Levels
between  7.8  mmol/l  (140  mg/dl)  and  11.1  mmol/l
(200 mg/dl)  are  deﬁned  as  ‘‘impaired  glucose
tolerance’’. A  glucose  level  above  11.1  mmol/l
(200 mg/dl)  at  2  h conﬁrms  a  diagnosis  of  diabetes
[5].
Statistical analysis
The  data  were  analyzed  using  the  statistical
package for  social  sciences  (SPSS)  version  8.0  soft-
ware. The  signiﬁcance  of  differences  between  the
mean values  of  the  study  variables  was  evaluated
by t-test.  The  signiﬁcance  of  differences  between
proportions was  performed  using  the  Chi-squared
test. Correlation  coefﬁcients  (r)  between  quantita-
tive variables  were  calculated.  A  P  value  less  than
0.05 was  considered  signiﬁcant.
Result
Thirty  patients  were  included  in  this  study,  and  the
diagnosis was  made  by  a  combination  of  clinical
data and  skin  biopsy.  All  the  patients  were  thought
to have  contracted  the  disease  in  their  country,
and they  did  not  have  history  of  diabetes  mellitus.
The features  at  presentation  included  anesthetic




pP  value  0.88  0.56
56.6%),  and  peripheral  nerve  enlargement  in  25
83.3%) of  the  patients.  Of  these,  16  patients  were
ales and  14  were  females,  varying  in  age  from  22
ears to  48  years  with  a  mean  age  of  34.9  years
Tables 2  and  3).  Of  the  30  cases,  12  patients  had
epromatous  leprosy,  9  had  dimorphous  leprosy  (BT,
B, BL)  and  9  had  tuberculoid  leprosy.  It  has  been
bserved  that  the  frequency  of  diabetes  mellitus
as much  greater  in  the  leprosy  patients  (13.3%)
ompared to  the  controls  (0.0%)  (Table  1).
The incidence  of  a diabetic  state  amongst  the
arious  types  of  leprosy  was  much  greater  in  the
epromatous  leprosy  cases  (25%,  or  3 out  of  12  cases
f lepromatous  leprosy)  compared  to  the  other
linical forms  of  leprosy  (Table  2).  In  addition,  the
ncidence of  a  pre-diabetic  state  (latent  diabetes)
mong  the  patients  with  various  types  of  leprosy
as much  greater  in  the  lepromatous  leprosy  cases
50%, or  6  cases  out  of  12  cases  of  lepromatous
eprosy) compared  to  the  other  clinical  forms  of
eprosy (Table  2).  The  incidence  of  diabetes  was
ot correlated  with  age  in  our  study.  Males  were
ore prone  to  diabetes  compared  to  females
Table 2).  It  has  been  further  observed  that  there
ere signiﬁcant  increases  in  fasting  serum  insulin,
OMA-IR  and  pro-inﬂammatory  cytokine  tumor
ecrosis factor  alpha  (TNF)  in  leprosy  patients
hen compared  with  the  control  group  (Table  4).  It
as also  observed  that  pro-inﬂammatory  cytokine
NF and  serum  cortisone  levels  among  the
atients with  various  types  of  leprosy  were  much
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Table  4  HOMA-IR,  serum  insulin,  TNF, IL6  and  cortisone  in  the  groups  studied.
Leprosy  patients  Control  P  value
Mean  ±  SD  Mean  ±  SD
HOMA-IR 3.56  ±  2.1  2.38  ±  1.06  0.04*
S
S.  insulin 13.08 ±  7.12  10.19  ±  3.58  0.14
NS
TNF 12.16 ±  4.2  6.67 ±  1.35  0.000**
HS
Cortisone  369.9  ±  202.38  202.8  ±  80.3  0.000**
HS
* P < 0.05 (S = signiﬁcant).
** P < 0.01 (HS = highly signiﬁcant).
P > 0.05 (NS = non signiﬁcant).
Table  5  HOMA-IR,  serum  insulin,  TNF, IL6  and  cortisone  in  clinical  types  of  leprosy.
TT  B  Ll  P1  P2  P3
Mean  ±  SD  Mean  ±  SD  Mean  ±  SD
HOMA-IR  2.84  ±  2.3  3.35  ±  1.29  4.17  ±  2.44  0.6  0.19  0.35
S.  insulin 10.23  ±  6.91  13.49  ±  4.69  14.36  ±  8.8  0.35  0.23  0.77








TT, tubercliod leprosy; BB, borderline leprosy; Ll, lepromatous leprosy; P1, TT versus BB; P2, TT versus LL; P3, BB versus LL.







































c** P < 0.01 (HS = highly signiﬁcant).
P > 0.05 (NS = non signiﬁcant).
igher  in  lepromatous  leprosy  cases  compared  to
he other  clinical  forms  of  leprosy  (Table  5).
iscussion
echanistically,  leprosy  offers  an  attractive  model
or investigations  of  the  pathogenic  correlation
etween the  patterns  of  inﬂammation  at  the  poles
f its  spectrum  and  the  hormonal  disarrangements
bserved in  this  disease.  Clinically,  it  is  impor-
ant that  those  involved  in  leprosy  management  be
ware of  the  potential  endocrine  changes.  One  of
hese changes  is  diabetes  mellitus  [1].
The exact  nature  of  the  association  between
iabetes and  leprosy  has  not  yet  been  clearly
lucidated. Diabetes  depresses  a  person’s  immu-
ity initially,  and  the  main  killer  cells  speciﬁc  to
ycobacterium  are  not  fully  activated  in  diabet-
cs. Thus,  early  diagnosis  and  treatment  of  diabetes
n leprosy  patients  is  important  to  reduce  the
ncidence of  complications  and  the  duration  of
dmission  to  the  hospital.  In  this  study,  we  have




fellitus  and  leprosy  and  to  clarify  the  role  of  lep-
osy in  the  pathogenesis  of  diabetes  mellitus.
We observed  that  the  incidence  of  impaired  glu-
ose tolerance  and  diabetic  state  among  the  various
ypes of  leprosy  was  much  higher  in  lepromatous
eprosy cases  compared  to  the  other  clinical  forms
f leprosy.  In  addition,  we  found  that  impaired
lucose tolerance  in  leprosy  is  much  higher  than
n overt  diabetes.  This  result  may  be  attributed
o several  factors.  For  example,  the  severity  and
cuteness  of  infection  and  stress,  which  are  pre-
ominantly  catabolic,  are  an  important  cause  of
he development  of  impaired  glucose  tolerance.
ever, protracted  inactivity  and  malnutrition  stim-
late the  stress  hormones  epinephrine,  glucagon,
ortisone and  growth  hormone,  which  act  synergis-
ically  to  raise  the  blood  sugar  level  in  excess  of
00 mg/dl  [6].  In  this  study,  we  found  a highly  signif-
cant increase  in  cortisone  levels  in  leprosy  patients
ompared  with  the  control  group.  It  has  also  been
stablished  that  serum  cortisone  levels  among  the
arious types  of  leprosy  were  much  higher  in  lep-
omatous  leprosy  cases  compared  to  other  clinical
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Furthermore,  we  observed  that  pro-
inﬂammatory  cytokine  TNF levels  were
signiﬁcantly higher  in  the  patient  group  than  in  the
control group.  Similarly,  pro-inﬂammatory  cytokine
TNF was  much  higher  in  lepromatous  leprosy  cases
than in  the  other  clinical  forms  of  leprosy.  Sev-
eral previous  studies  evaluated  TNF  production  in
patients with  leprosy  and  reported  that  serum  TNF
concentrations,  as  measured  by  an  ELISA,  were
higher in  individuals  with  the  lepromatous  form  of
the disease  [7].  Because  the  total  number  of  skin
lesions  and  the  total  number  of  mononuclear  cells
exposed  to  M.  leprae  are  far  higher  in  lepromatous
leprosy patients,  the  total  TNF secretory  capacity
of lepromatous  leprosy  patients  may  result  in
higher  serum  TNF  levels,  although  the  biological
effect may  be  diminished  by  circulating  inhibitors
[8]. TNF may  contribute  to  protective  immunity
against mycobacteria  and  other  intracellular  orga-
nisms through  the  production  of  reactive  nitrogen
intermediates.  TNF  enhances  the  production  of
nitric oxide  by  murine  macrophages  [8].  Nitric
oxide has  been  shown  to  inhibit  the  growth  of
and/or  to  kill  Leishmaniae  [9],  M.  leprae  [10],  and
Mycobacterium  tuberculosis  [8].
The  pro-inﬂammatory  cytokine  TNF  plays  an
important  role  in  the  development  of  type  2  dia-
betes.  A  number  of  studies  have  described  a direct
role for  TNF  in  the  pathophysiology  of  insulin
resistance. In  vitro  studies  have  shown  that  TNF-
down  regulates  insulin  receptor  signaling  in  cul-
tured adipocytes,  hepatocytes  [11],  and  skeletal
muscle  [12].  Furthermore,  increased  TNF  is  asso-
ciated with  insulin  resistance  in  a  broad  range  of
conditions,  including  obesity  [11]  and  aging  [13],
and after  muscle  damage  [14].  TNF  activates
a pathway  that  increases  sphingomyelinase  and
ceramides  and  appears  to  interfere  with  insulin
receptor  autophosphorylation.  Recently,  it  has  been
shown that  TNF  induces  insulin  resistance  by
promoting serine  phosphorylation  of  the  insulin
receptor  substrate  (IRS)-1,  thus  impairing  its  asso-
ciation with  the  insulin  receptor  [15].  In  our  study,
leprosy  patients  had  signiﬁcantly  higher  levels  of
HOMA-IR than  healthy  controls.  Insulin  resistance
is an  important  contributor  to  the  pathogenesis  of
type 2  diabetes.
Additionally,  there  is evidence  that  TNF  partici-
pates  in  dysregulation  of  the  hepatic  glucose  output
[16] and  inhibits  glucose-induced  insulin  secretion
[17].  Plasma  levels  of  IL-1  and  TNF  are  also  raised
in cases  of  severe  illness,  which  can  stimulate  the
anti-insulin  hormones  [18,19]Another cause  for  the  higher  glucose  tolerance
in leprosy  could  be  due  to  a  family  of  fatty-acid-
transporter proteins  in  the  mycobacterium  bacillusM.A.  Saraya  et  al.
hat  may  cause  dysregulation  of  energy  homeostasis
n the  disease  [20].  When  expressed  in  mammalian
epatocytes, the  fatty  acid  transporter  protein
ene of  mycobacterium  preferentially  increases  the
ptake of  long  chain  fatty  acids  (LCFAs).  LCFAs
re an  important  source  of  energy  for  most  orga-
isms,  and  they  also  function  as  blood  hormones,
egulating key  functions  such  as  hepatic  glucose
etabolism  [20].
Another  factor  that  could  play  a  role  in  glucose
olerance in  leprosy  patients  is  the  effect  of  anti-
eprosy  drugs  on  blood  sugar  levels.  Rifampicin  is
ne of  the  drugs  that  is  used  in  the  treatment  of
eprosy over  long  periods.  Rifampicin  is  a powerful
nducer of  the  hepatic  microsomal  enzyme  system
nd frequently  interacts  with  other  drugs.  It lowers
he serum  levels  of  sulfonyl  ureas  and  biguanides
21]. Hence,  patients  with  co-existing  diseases
hould have  their  doses  of  oral  anti-diabetic  drugs
djusted  upwards  according  to  plasma  glucose  con-
entration.  Takasu  et  al.  observed  that  rifampicin
nduced an  early  phase  hyperglycemia  that  they
ttributed  to  augmented  intestinal  absorption  [22].
owever, no  case  of  overt  diabetes  was  observed,
nd it  was  believed  that  rifampicin  is  not  diabeto-
enic.  Rifabutin,  a  newer  rifamycin,  also  induces
epatic  metabolism  but  is  not  as  potent  an  inducer
s rifampicin  [23].
onclusion
ur  ﬁndings  indicate  that  the  frequency  of  diabetes
ellitus  is  higher  in  leprosy  patients  than  in  con-
rols. Based  on  this  ﬁnding,  we  recommend  that
he clinicians  who  treat  leprosy  should  consider  dia-
etes mellitus  in  patients  with  leprosy,  as  diabetes
ay complicate  and  delay  the  management  of  lep-
osy.
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